Annual Report — Form 10-K Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 1.88M
2: EX-4.2 Instrument Defining the Rights of Security Holders HTML 58K
3: EX-10.16 Material Contract HTML 59K
4: EX-10.17 Material Contract HTML 52K
5: EX-10.18 Material Contract HTML 56K
6: EX-21.1 Subsidiaries List HTML 43K
7: EX-23 Consent of Expert or Counsel HTML 40K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 45K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 45K
10: EX-32 Certification -- §906 - SOA'02 HTML 42K
17: R1 Cover HTML 104K
18: R2 Consolidated Balance Sheets HTML 144K
19: R3 Consolidated Balance Sheets (Parenthetical) HTML 60K
20: R4 Consolidated Statements of Operations HTML 111K
21: R5 Consolidated Statements of Comprehensive Income HTML 68K
22: R6 Consolidated Statements of Cash Flows HTML 143K
23: R7 Consolidated Statements of Stockholders' Equity HTML 107K
24: R8 Description of Business HTML 43K
25: R9 Summary of Significant Accounting Policies HTML 123K
26: R10 Intellectual Property Litigation Expenses, Net HTML 44K
27: R11 Special Charges (Gain) HTML 44K
28: R12 Other Consolidated Financial Statement Details HTML 104K
29: R13 Leases HTML 60K
30: R14 Investments HTML 135K
31: R15 Acquisitions HTML 62K
32: R16 Goodwill and Other Intangible Assets HTML 90K
33: R17 Debt and Credit Facilities HTML 59K
34: R18 Fair Value Measurements HTML 125K
35: R19 Derivative Instruments and Hedging Activities HTML 162K
36: R20 Employee Benefit Plans HTML 185K
37: R21 Common Stock HTML 113K
38: R22 Accumulated Other Comprehensive Loss HTML 136K
39: R23 Other Income, Net HTML 53K
40: R24 Income Taxes HTML 182K
41: R25 Legal Proceedings HTML 47K
42: R26 Segment Information HTML 125K
43: R27 Quarterly Financial Results and Market for the HTML 86K
Company's Stock (Unaudited)
44: R28 Valuation and Qualifying Accounts HTML 68K
45: R29 Subsequent Event HTML 43K
46: R30 Summary of Significant Accounting Policies HTML 149K
(Policies)
47: R31 Summary of Significant Accounting Policies HTML 75K
(Tables)
48: R32 Other Consolidated Financial Statement Details HTML 119K
(Tables)
49: R33 Leases (Tables) HTML 61K
50: R34 Investments (Tables) HTML 133K
51: R35 Acquisitions (Tables) HTML 50K
52: R36 Goodwill and Other Intangible Assets (Tables) HTML 123K
53: R37 Debt and Credit Facilities (Tables) HTML 58K
54: R38 Fair Value Measurements (Tables) HTML 118K
55: R39 Derivative Instruments and Hedging Activities HTML 211K
(Tables)
56: R40 Employee Benefit Plans (Tables) HTML 185K
57: R41 Common Stock (Tables) HTML 111K
58: R42 Accumulated Other Comprehensive Loss (Tables) HTML 139K
59: R43 Other Income, Net (Tables) HTML 53K
60: R44 Income Taxes (Tables) HTML 178K
61: R45 Segment Information (Tables) HTML 122K
62: R46 Quarterly Financial Results and Market for the HTML 86K
Company's Stock (Unaudited) (Tables)
63: R47 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 52K
Revenue (Narrative) (Details)
64: R48 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 45K
Shipping and Handling Costs (Narrative) (Details)
65: R49 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 44K
Investments (Narrative) (Details)
66: R50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 45K
Accounts Receivable (Details)
67: R51 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 51K
Inventories (Narrative) (Details)
68: R52 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 57K
Property, Plant, and Equipment (Narrative)
(Details)
69: R53 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 49K
Goodwill and Intangible Assets (Narrative)
(Details)
70: R54 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 72K
Schedule of Computation of Basic and Diluted
Earnings Per Share (Details)
71: R55 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 45K
Earnings per Share (Narrative) (Details)
72: R56 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 55K
Schedule of Stock-Based Compensation Expense
(Details)
73: R57 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 44K
Stock-based Compensation (Narrative) (Details)
74: R58 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - HTML 42K
Derivatives (Narrative) (Details)
75: R59 Intellectual Property Litigation Expenses, Net HTML 58K
(Details)
76: R60 Special Charges (GAIN) - Impairment of Long-lived HTML 52K
Assets (Details)
77: R61 Special Charges (GAIN) - Acquisition of HTML 44K
Intellectual Property (Details)
78: R62 Special Charges (GAIN) - Realignment Expenses HTML 45K
(Details)
79: R63 OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - HTML 106K
Schedule of Components of Selected Captions
(Details)
80: R64 OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - HTML 42K
Narrative (Details)
81: R65 OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - HTML 59K
Supplemental Cash Flow Information (Details)
82: R66 OTHER CONSOLIDATED FINANCIAL STATEMENT DETAILS - HTML 53K
Cash, Cash Equivalents, and Restricted Cash
(Details)
83: R67 LEASES - Narrative (Details) HTML 51K
84: R68 LEASES - Assets and Liabilities of Operating HTML 48K
Leases (Details)
85: R69 LEASES - Maturities Of Operating Lease Liabilities HTML 64K
(Details)
86: R70 INVESTMENTS - Schedule of Investments in Debt HTML 85K
Securities (Details)
87: R71 INVESTMENTS - Schedule of Cost and Fair Value of HTML 84K
Investments in Debt Securities, by Contractual
Maturity (Details)
88: R72 INVESTMENTS - Narrative (Details) HTML 54K
89: R73 INVESTMENTS - Schedule of Unrealized Losses on HTML 65K
Debt Securities (Details)
90: R74 INVESTMENTS - Schedule of Investments in HTML 49K
Unconsolidated Affiliates (Details)
91: R75 ACQUISITIONS - CAS Medical Systems, Inc. HTML 57K
(Narrative) (Details)
92: R76 ACQUISITIONS - Summary of Fair Values of Assets HTML 69K
Acquired and Liabilities Assumed (Details)
93: R77 ACQUISITIONS - Harpoon Medical, Inc. (Narrative) HTML 57K
(Details)
94: R78 ACQUISITIONS - Valtech Cardio, Ltd. (Narrative) HTML 85K
(Details)
95: R79 ACQUISITIONS - CardiAQ Valve Technologies, Inc. HTML 58K
(Narrative) (Details)
96: R80 GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative HTML 51K
(Details)
97: R81 GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of HTML 57K
Changes in the Carrying Amount of Goodwill, by
Segment (Details)
98: R82 GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of HTML 68K
Other Intangible Assets (Details)
99: R83 GOODWILL AND OTHER INTANGIBLE ASSETS - Schedule of HTML 52K
Estimated Amortization Expense (Details)
100: R84 DEBT AND CREDIT FACILITIES - Narrative (Details) HTML 86K
101: R85 DEBT AND CREDIT FACILITIES - Summary of the Notes HTML 59K
(Details)
102: R86 FAIR VALUE MEASUREMENTS - Summary of Financial HTML 127K
Instruments Measured at Fair Value on a Recurring
Basis (Details)
103: R87 FAIR VALUE MEASUREMENTS - Summary of Changes in HTML 46K
Fair Value of Contingent Consideration Obligation
(Details)
104: R88 FAIR VALUE MEASUREMENTS - Narrative (Details) HTML 69K
105: R89 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - HTML 47K
Summary of Derivative Financial Instruments Used
to Manage Currency Exchange and Interest Rate Risk
(Details)
106: R90 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - HTML 59K
Schedule of Location and Fair Value Amounts of
Derivative Instruments (Details)
107: R91 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - HTML 85K
Schedule of Effect of Master-Netting Agreements
and Rights of Offset (Details)
108: R92 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - HTML 73K
Schedule of Effect of Derivative Instruments
(Details)
109: R93 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - HTML 77K
Schedule of Location of Gain or Loss on Derivative
Instruments (Details)
110: R94 DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - HTML 51K
Narrative (Details)
111: R95 EMPLOYEE BENEFIT PLANS - Schedule of Information HTML 108K
Regarding Defined Benefit Pension Plans (Details)
112: R96 EMPLOYEE BENEFIT PLANS - Narrative (Details) HTML 70K
113: R97 EMPLOYEE BENEFIT PLANS - Components of Net HTML 64K
Periodic Benefit Cost (Details)
114: R98 EMPLOYEE BENEFIT PLANS - Schedule of HTML 68K
Weighted-Average Assumptions Used to Determine
Benefit Obligations (Details)
115: R99 EMPLOYEE BENEFIT PLANS - Schedule of Target HTML 115K
Weighted-Average Asset Allocations and Fair Value
(Details)
116: R100 EMPLOYEE BENEFIT PLANS - Summary of Changes in HTML 56K
Fair Value of Defined Benefit Plan Assets
Classified as Level 3 (Details)
117: R101 EMPLOYEE BENEFIT PLANS - Schedule of Benefit HTML 53K
Payments Which Reflect Expected Future Service
(Details)
118: R102 COMMON STOCK - Treasury Stock (Narrative) HTML 52K
(Details)
119: R103 COMMON STOCK - Accelerated Share Repurchases HTML 85K
(Details)
120: R104 COMMON STOCK - Employee and Director Stock Plans HTML 99K
(Narrative) (Details)
121: R105 COMMON STOCK - Schedule of Weighted-Average HTML 59K
Assumptions (Details)
122: R106 COMMON STOCK - Schedule of Stock Option (Details) HTML 91K
123: R107 COMMON STOCK - Schedule of Restricted Stock Unit HTML 64K
Activity (Details)
124: R108 COMMON STOCK - Schedule of Restricted Stock Unit HTML 46K
Activity (Narrative) (Details)
125: R109 COMMON STOCK - Additional Information (Narrative) HTML 54K
(Details)
126: R110 ACCUMULATED OTHER COMPREHENSIVE LOSS - Summary of HTML 89K
Activity for Each Component of Accumulated Other
Comprehensive Loss (Details)
127: R111 ACCUMULATED OTHER COMPREHENSIVE LOSS - Change in HTML 81K
Unrealized Pension Costs (Details)
128: R112 ACCUMULATED OTHER COMPREHENSIVE LOSS - Schedule of HTML 90K
Information About Amounts Reclassified from
Accumulated Other Comprehensive Loss (Details)
129: R113 Other Income, Net (Details) HTML 52K
130: R114 INCOME TAXES - Schedule of Income Before HTML 49K
Provisions for Income Taxes (Details)
131: R115 INCOME TAXES - Provision for Income Taxes HTML 69K
(Details)
132: R116 INCOME TAXES - Components of Deferred Tax Assets HTML 89K
and Liabilities (Details)
133: R117 INCOME TAXES - Narrative (Details) HTML 94K
134: R118 INCOME TAXES - Summary of Net Operating Loss HTML 81K
Carryforwards (Details)
135: R119 INCOME TAXES - Summary of Tax Credit Carryforwards HTML 61K
(Details)
136: R120 INCOME TAXES - Reconciliation of Federal Statutory HTML 71K
Income Tax Rate to Effective Income Tax Rate
(Details)
137: R121 INCOME TAXES - Reconciliation of Beginning and HTML 55K
Ending Amount of Uncertain Tax Positions (Details)
138: R122 Legal Proceedings (Details) HTML 49K
139: R123 SEGMENT INFORMATION - Schedule of Information HTML 70K
About Reportable Segments (Details)
140: R124 SEGMENT INFORMATION - Reconciliation of Segment HTML 87K
Net Sales and Pre-Tax Income to Consolidated Net
Sales and Pre-Tax Income (Details)
141: R125 SEGMENT INFORMATION - Schedule of Enterprise-Wide HTML 80K
Information (Details)
142: R126 Quarterly Financial Results and Market for the HTML 79K
Company's Stock (Unaudited) (Details)
143: R127 Quarterly Financial Restults and Market for the HTML 59K
Company's Stock (UNAUDITED) - Narrative (Details)
144: R128 Valuation and Qualifying Accounts (Details) HTML 55K
145: R129 Subsequent Event (Details) HTML 49K
147: XML IDEA XML File -- Filing Summary XML 285K
16: XML XBRL Instance -- ew-20201231_htm XML 5.37M
146: EXCEL IDEA Workbook of Financial Reports XLSX 199K
12: EX-101.CAL XBRL Calculations -- ew-20201231_cal XML 506K
13: EX-101.DEF XBRL Definitions -- ew-20201231_def XML 1.51M
14: EX-101.LAB XBRL Labels -- ew-20201231_lab XML 3.21M
15: EX-101.PRE XBRL Presentations -- ew-20201231_pre XML 2.13M
11: EX-101.SCH XBRL Schema -- ew-20201231 XSD 294K
148: JSON XBRL Instance as JSON Data -- MetaLinks 731± 1.13M
149: ZIP XBRL Zipped Folder -- 0001099800-21-000007-xbrl Zip 1.09M
1.I have reviewed this annual report on Form 10-K of Edwards Lifesciences Corporation;
2.Based
on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's
auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
